

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**ZJ**

**中基長壽科學**

ZHONG JI LONGEVITY SCIENCE

**Zhong Ji Longevity Science Group Limited**

**中基長壽科學集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 767)**

**INSIDE INFORMATION**

**(1) DELAY IN PUBLICATION OF  
THE 2022 AUDITED ANNUAL RESULTS ANNOUNCEMENT;  
(2) POTENTIAL DELAY IN DESPATCH OF  
THE 2022 ANNUAL REPORT;  
(3) POSTPONEMENT OF BOARD MEETING;  
AND  
(4) SUSPENSION OF TRADING**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

**DELAY IN PUBLICATION OF THE 2022 ANNUAL RESULTS**

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish an announcement for the annual results of the Group for the year ended 31 December 2022 (the “**2022 Annual Results**”) on a date not later than three months after the end of the financial year of the Company, namely, on or before 31 March 2023. Under Rule 13.49(2)

of the Listing Rules, the preliminary announcement in relation to the 2022 Annual Results shall be based on the Group's consolidated financial statements for the financial year ended 31 December 2022 which shall have been agreed with the Company's auditor.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to inform its shareholders (the "**Shareholders**") and potential investors that the preparation for the audit of the financial statements of the Group for the year ended 31 December 2022 has been delayed mainly being the issuing and receiving of audit confirmations for banks, creditors or debtors of the Group (the "**Audit Confirmation Procedures**"), could not be completed as scheduled. Also, certain confirmations from external valuation reports are yet to be finalized. As such, the Auditor requires more time for conducting the audit of the 2022 annual results and the Company may not be able to publish the audited 2022 Annual Results on or before 31 March 2023 in accordance with Rule 13.49(1) of the Listing Rules.

The Board and the management of the Company are using their best efforts to expedite the audit progress. Based on the information currently available to the Company and present confirmation from the auditors, the Company expects that the audited 2022 Annual Results with clean report will be published on or before 18 April 2023, in considering the upcoming April month public holidays.

The Board hereby confirms that the Company is operating as usual.

#### **POTENTIAL DELAY IN DESPATCH OF THE 2022 ANNUAL REPORT**

Pursuant to Rule 13.46(2)(a) of the Listing Rules, the Company is required to despatch its annual report for year ended 31 December 2022 (the "**2022 Annual Report**") to the Shareholders no later than four months after the end of the financial year (i.e., on or before 30 April 2023). Due to the delay in the publication of the 2022 Annual Results, it is expected that there may potentially be a delay in the despatch of the 2022 Annual Report.

The potential delay in the despatch of the 2022 Annual Report would, if materialised, constitute non-compliance with Rule 13.46(2)(a) of the Listing Rules. Further announcement(s) will be made by the Company to inform the Shareholders of the expected date of despatch of the 2022 Annual Report as and when appropriate in accordance with the Listing Rules and/or the SFO.

#### **POSTPONEMENT OF BOARD MEETING**

Reference is made to the announcement of the Company dated 21 March 2023 in relation to a meeting of the Board (the "**Board Meeting**") to be held on 31 March 2023 for the purpose of, amongst other matters, considering and approving the announcement of the 2022 Annual Results and the publication of the same and considering the recommendation of a final dividend, if any. Due to the aforesaid delay in the

publication of the 2022 Annual Results, the Board Meeting will be postponed. Further announcement(s) will be made by the Company to inform the Shareholders of the date of the Board Meeting as and when appropriate in accordance with the Listing Rules.

Save as disclosed above, as at the date of this announcement, the Company does not possess any other inside information which is subject to disclosure requirements under the Listing Rules.

## **SUSPENSION OF TRADING**

Pursuant to Rule 13.50 of the Listing Rules, the Stock Exchange will normally require suspension of trading in an issuer's securities an issuer fails to publish periodic financial information in accordance with the Listing Rules, and the suspension will remain in force until the issuer publishes an announcement containing the requisite financial information and other information constituting inside information of the Company. Accordingly, it is expected that trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on Monday, 3 April 2023, until the 2022 Annual Results are published by the Company.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Zhong Ji Longevity Science Group Limited**  
**Yan Li**  
*Chairman*

Hong Kong, 31 March 2023

As at the date of this announcement, the Directors are:

*Executive Directors*

Mr. Yan Li (*Chairman*)  
Mr. Yan Yifan (*Chief Executive Officer*)  
Mr. Li Xiaoshuang  
Ms. Cao Xie Qiong

*Independent non-executive Directors*

Mr. Lee See Barry  
Mr. Wang Ning  
Prof. Huang Cibo

*Non-executive Directors*

Dr. He Yiwu  
Mr. Lyn Changsheng

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*